1. Medtech Insight
  2. >>Business

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

Chalmers University of Technology spin out takes a different route to cancer biomarker identification

 
• By Ashley Yeo

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Start-up Spotlight

Diagnostic tools have rarely had such concerted attention as during COVID-19. And science advances have been moving modern diagnostic techniques, such as circulating tumor DNA biomarkers, epigenetic markers, DNA methylation and RNA screening, up the agenda.

But those technologies are not particularly sensitive to the early stages of cancer, said Elypta CEO Karl Bergman. The company instead has a focus on identifying cancer biomarkers based on...

Elypta was founded in 2017 by the university’s Jens Nielsen, a professor in systems biology, and his PHd student, Francesco Gatto. Nielsen, who runs what is claimed to...

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.